CCM
BTAI icon

Connective Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Connective Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,063
Closed -$97.3K – 41
2023
Q4 		$97.3K Buy
+2,063
New +$115K 0.08% 77

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connective Capital Management's BTAI Position: Q1 2024 in Review

Connective Capital Management sold out of BioXcel Therapeutics (BTAI) in Q1 2024, closing a stake of 2,063 shares — an estimated $97.3K sold.

Connective Capital Management first reported a position in BTAI in Q4 2023 and held it in 1 quarter. The position peaked at $97.3K in Q4 2023. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Connective Capital Management reported no remaining BioXcel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Connective Capital Management sold 2,063 BioXcel Therapeutics shares in Q1 2024, an estimated $97.3K.
  • Connective Capital Management first reported a position in BioXcel Therapeutics in Q4 2023 and held it in 1 quarter.
  • Connective Capital Management's BioXcel Therapeutics position peaked at $97.3K in Q4 2023.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Connective Capital Management's 13F filing for Q1 2024, filed 16 May 2024.